Genetron Holdings Limited (“Genetron Health” or the “Company”,
Nasdaq: GTH), a leading precision oncology platform company in
China that specializes in offering molecular profiling tests, early
cancer screening products and companion diagnostics development,
today announced the release of 10 research results at the 2022
American Society of Clinical Oncology (ASCO) Annual Meeting.
Based on Genetron Health’s patented One-Step™ Seq Method and
core products such as Onco PanScan™, the results aimed to
contribute to the scientific research and clinical practice of
full-cycle cancer management.
These studies involved an in-depth analysis of the Chinese
population and focused on analyzing the characteristics of gene
mutations and fusion mapping of multiple cancer types, including
lung cancer and gastric cancer, guiding clinical diagnosis and
treatment through molecular characteristics and predicting the
efficacy of immune checkpoint inhibitors (ICIs) by screening
potential biomarkers of immunotherapy. Integrated with clinical
data, these results emerged from joint studies that Genetron Health
conducted with more than 10 leading hospitals and scientific
research institutes in China.
“These research results presented at ASCO 2022, which are all
based on Genetron Health's patented technology and innovative
products, explore the genomics characteristics of multi-cancer
types and the clinical application of products,” said Dr. Yunfu Hu,
Genetron Health’s Chief Medical Officer. “In the future, Genetron
Health's products and technologies will continue to drive the
patients’ full-cycle cancer care and contribute to accurate
clinical diagnosis and treatment.”
The 10 research results released by Genetron Health at ASCO 2022
mainly focused on the three following areas:
Gene mutation and fusion mapping support explaining
cancer pathogenesis and developing personalized
therapy
Based on next-generation sequencing (NGS), studies #e20530,
#8530, #e15124, #3121 explored gene mutation of METex14 skipping,
the coexistence of ALK fusions and other driver mutations, and ROS1
fusions, respectively. The results indicated the characteristics
and patterns of gene fusions and coexistence of driver mutations,
aiming to better explain the pathogenesis of cancers and further
develop the value of personalized drug therapies such as TKIs.
Molecular characteristics guide clinical diagnosis and
treatment
Currently, little is known about molecular features of patients
with synchronous multiple primary colorectal cancer (sMPCC) in
clinical practice. Adopting immunofluorescence (IHC) and Genetron
Health’s NGS-based Onco PanScan™ technology, study #3601
revealed that deficient mismatch repair (MMR) or microsatellite
instability (MSI)-high frequencies in sMPCC were significantly
higher than those in single primary CRC. Therefore, it is
recommended that, before receiving treatment, synchronous MPCC
patients shall be examined to identify their MMR or MSI status for
each lesion and be divided into three subgroups accordingly.
Patients with different MMR or MSI status should be treated with
personalized therapies for better management of their disease.
Drug therapy has always been a challenge for gastric cancer.
Although HER2-directed therapy and ICIs have achieved great
success, there is still an urgent need to develop other valid
targeted drugs. Study #e16061 retrospectively investigated the
relationship of gene fusions with driver mutations, MSI, TMB (tumor
mutation burden), and MMR in gastric cancer tissue samples from
Chinese patients, indicating that targetable fusion testing should
be advised to patients with disease progression after receiving
standard therapy.
Small bowel adenocarcinoma (SBA) is a rare gastrointestinal
cancer with a poor prognosis and limited treatment options. Study
#4159 adopted Genetron Health's Onco PanScan™, a deep sequencing
panel, to conduct an analysis of the comprehensive genomic
characterization of 84 Chinese SBA patients, and revealed that at
least 39% of the patients in the cohort harbored actionable genetic
alterations. The study provided a reference for precision diagnosis
and treatment, and genomically matched clinical trials.
Screening of potential immunotherapy biomarkers to
predict the efficacy of ICIs
Through analyzing data from The Cancer Genome Atlas (TCGA)
cohorts, Memorial Sloan Kettering Cancer Center (MSKCC) cohorts and
Genetron Health’s Chinese cohort, studies #e14536, #e16083, #e14581
explored the values of loss-of-function of Polybromo 1(PBRM1)
mutations, inactivation of chromatin remodeling complexes, and TP53
mutations as the potential predictor for ICIs efficacy.
Abstract# |
Title |
e20530 |
Characterization of MET exon 14 skipping in pan-cancer |
|
|
8530 |
Driver coexistence characteristics of ALK-fusion in Chinese lung
cancer |
|
|
e15124 |
Analysis of ROS1 fusions in nonlung solid tumors |
|
|
3121 |
Molecular characterization of cancers with ALK gene fusions in
nonlung tumors |
|
|
e14536 |
Pan-cancer analysis of PBRM1 mutation and their association with
immune-related biomarkers and prognosis |
|
|
e16083 |
Genomic alteration in chromatin remodeling genes as a potential
predictive biomarker for immunotherapy in gastric cancer |
|
|
e16061 |
Detection of targetable fusion alterations in gastric cancer in the
Chinese population |
|
|
4159 |
Evaluation of somatic and germline variants in patients with small
bowel adenocarcinoma reveals clinically actionable targets |
|
|
3601 |
Molecular typing and clinical characteristics of synchronous
multiple primary colorectal cancer |
|
|
e14581 |
Investigating the various predictive values of TP53 mutations for
response to immune checkpoint inhibitors (ICIs) in different solid
tumors |
|
|
About Genetron Holdings Limited
Genetron Holdings Limited (“Genetron Health” or the “Company”)
(Nasdaq: GTH) is a leading precision oncology platform company in
China that specializes in cancer molecular profiling and harnesses
advanced technologies in molecular biology and data science to
transform cancer treatment. The Company has developed a
comprehensive oncology portfolio that covers the entire spectrum of
cancer management, addressing needs and challenges from early
screening, diagnosis and treatment recommendations, as well as
continuous disease monitoring and care. Genetron Health also
partners with global biopharmaceutical companies and offers
customized services and products. For more information, please
visit ir.genetronhealth.com.
Safe Harbor Statement
This press release contains forward-looking statements. These
statements are made under the “safe harbor” provisions of the U.S.
Private Securities Litigation Reform Act of 1995. Statements that
are not historical facts, including statements about the Company’s
beliefs and expectations, are forward-looking statements.
Forward-looking statements involve inherent risks and
uncertainties, and a number of factors could cause actual results
to differ materially from those contained in any forward-looking
statement. In some cases, forward-looking statements can be
identified by words or phrases such as “may”, “will,” “expect,”
“anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,”
“believe,” “potential,” “continue,” “is/are likely to” or other
similar expressions. Further information regarding these and other
risks, uncertainties or factors is included in the Company’s
filings with the SEC. All information provided in this press
release is as of the date of this press release, and the Company
does not undertake any duty to update such information, except as
required under applicable law.
Investor Relations Contact
Email: ir@genetronhealth.com
Media Relations Contact
Yanrong Zhao
Email: yanrong.zhao@genetronhealth.com
Grafico Azioni Genetron (NASDAQ:GTH)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Genetron (NASDAQ:GTH)
Storico
Da Giu 2023 a Giu 2024